Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
4 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
28 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (1 thèse dirigée)
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
13ans d'exercice (thèse 2013)
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
Source theses.fr — signal de direction d'équipe / statut PU-PH (à confirmer via le site universitaire).
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
36
36 articles ont été cités au moins 36fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
6 455
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
229
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
79
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Hôpital Necker-Enfants Malades · Centre National de la Recherche Scientifique · Inserm
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Association of eating disorders and/or insulin omission with impaired glycaemic control in persons living with type 1 diabetes: cross-sectional analysis of the French SFDT1 study
2026ArticleBMJ Open
Psychosocial outcomes among adults with type 1 diabetes using a tubeless automated insulin delivery system compared with sensor augmented pump therapy: A randomised, parallel‐group clinical trial sub‐study
2026ArticleDiabetes, Obesity and Metabolism
Severity of complications is associated with impaired health‐related quality of life in people with type 1 diabetes
2026ArticleDiabetes, Obesity and Metabolism
A nationwide 12‐month observatory of automated insulin delivery shows improved glucose control, sustained adoption, and reduced acute severe events
2026ArticleDiabetes, Obesity and Metabolism
Psychosocial burden in type 1 diabetes: a cross-sectional network analysis in the SFDT1 study
2026ArticleBMJ Open
Musculoskeletal disorders in type 1 diabetes: Clinical phenotyping and associations with quality of life and glucose control - The French SFDT1 cohort study
2025ArticleDiabetes & Metabolism
Beyond overweight, visceral adiposity is associated with estimation of cardiovascular risk in patients living with type 1 diabetes: findings from the SFDT1 cohort
2025ArticleCardiovascular Diabetology
Clinical phenotyping of people living with type 1 diabetes according to their levels of diabetes-related distress: results from the SFDT1 cohort
2025ArticleBMJ Open Diabetes Research & Care
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
GHU APHP NUP SITE LARIBOISIERE
2 R AMBROISE PARE, 75475 PARIS CEDEX 10
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Diabetes care · 2024
OBJECTIVE To examine the efficacy and safety of the tubeless Omnipod 5 automated insulin delivery (AID) system compared with pump therapy with a continuous glucose monitor (CGM) in adults with type 1 diabetes with suboptimal glycemic outcomes. RESEARCH DESIGN AND METHODS In this 13-week multicenter, parallel-group, randomized controlled trial performed in the U.S. and France, adults aged 18–70 years with type 1 diabetes and HbA1c 7–11% (53–97 mmol/mol) were randomly assigned (2:1) to intervention (tubeless AID) or control (pump therapy with CGM) following a 2-week standard therapy period. The primary outcome was a treatment group comparison of time in range (TIR) (70–180 mg/dL) during the trial period. RESULTS A total of 194 participants were randomized, with 132 assigned to the intervention and 62 to the control. TIR during the trial was 4.2h/day higher in the intervention compared with the control group (mean difference 17.5% [95% CI 14.0%, 21.1%]; P < 0.0001). The intervention group had a greater reduction in HbA1c from baseline compared with the control group (mean ± SD −1.24 ± 0.75% [−13.6 ± 8.2 mmol/mol] vs. −0.68 ± 0.93% [−7.4 ± 10.2 mmol/mol], respectively; P < 0.0001), accompanied by a significantly lower time <70 mg/dL (1.18 ± 0.86% vs. 1.75 ± 1.68%; P = 0.005) and >180 mg/dL (37.6 ± 11.4% vs. 54.5 ± 15.4%; P < 0.0001). All primary and secondary outcomes were met. No instances of diabetes-related ketoacidosis or severe hypoglycemia occurred in the intervention group. CONCLUSIONS Use of the tubeless AID system led to improved glycemic outcomes compared with pump therapy with CGM among adults with type 1 diabetes, underscoring the clinical benefit of AID and bolstering recommendations to establish AID systems as preferred therapy for this population.
Diabetes, obesity & metabolism · 2024
Abstract Aim The study aim was to evaluate the feasibility, safety and efficacy of automated insulin delivery (AID) assisted by home health care (HHC) services in people with type 2 diabetes unable to manage multiple daily insulin injections (MDI) at home on their own. Patients and Methods This was an open label, multicentre, randomized, parallel group trial. In total, 30 adults with type 2 diabetes using MDI and requiring nursing support were randomly allocated to AID or kept their usual therapy over a 12‐week period. Both treatments were managed with the support of HHC services. The primary outcome was the percentage time in the target glucose range of 70‐180 mg/dl (TIR). Secondary outcomes included other continuous glucose monitoring metrics, glycated haemoglobin (HbA1c) levels, daily insulin doses, body weight, and of quality of life scores, fear of hypoglycaemia and satisfaction questionnaires. Results Age (69.7 vs. 69.3 years) and HbA1c (9.25 vs. 9.0) did not differ in MDI and AID at baseline. Compared with MDI, AID resulted in a significant increase in TIR by 27.4% [95% CI (15.0‐39.8); p < .001], a decrease in time above range by 27.7% and an unchanged time below range of <1%. A between‐group difference in HbA1c was 1.3% favouring AID. Neither severe hypoglycaemia nor ketoacidosis occurred in either group. Patient and caregiver satisfaction with AID was high. Conclusions AID combined with tailored HHC services significantly improved glycaemic control with no safety issues in people with type 2 diabetes previously under an MDI regimen with HHC. AID should be considered a safe option in these people when lacking acceptable glucose control.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Diabetes, obesity & metabolism · 2026 · Journal Article
Riveline JP, Renard E, Aleppo G, Bode BW, et al.
Diabetologia · 2025 · Published Erratum
Lingvay I, Benamar M, Chen L, Fu A, et al.
Diabetologia · 2025 · Journal Article
Lingvay I, Benamar M, Chen L, Fu A, et al.
Diabetes care · 2024 · Journal Article
Renard E, Weinstock RS, Aleppo G, Bode BW, et al.
Diabetes, obesity & metabolism · 2024 · Randomized Controlled Trial
Reznik Y, Carvalho M, Fendri S, Prevost G, et al.
Diabetes, obesity & metabolism · 2022 · Journal Article
Renard E, Riveline JP, Hanaire H, Guerci B, et al.
Diabetes & metabolism · 2026 · Journal Article
Tatulashvili S, Hamamouche N, Sritharan N, Servy H, et al.
The Journal of clinical endocrinology and metabolism · 2025 · Journal Article
Camoin M, Mohammedi K, Saulnier PJ, Hadjadj S, et al.
BMJ open diabetes research & care · 2025 · Journal Article
Canha D, Aguayo G, Cosson E, Vaduva P, et al.
Diabetes, obesity & metabolism · 2026 · Journal Article
Guerci B, Blanc-Bisson C, Vicaut E, De Pouvourville G, et al.
BMJ open · 2026 · Journal Article
Aguayo GA, Martin VP, Canha D, Cosson E, et al.
Diabetes & metabolism · 2026 · Journal Article
Riveline JP, Hopley C, Olivieri AV, Guigand G, et al.
Diabetes, obesity & metabolism · 2026 · Journal Article
Barraud S, Aguayo GA, Cosson E, Amouyal C, et al.
Diabetes & metabolism · 2025 · Journal Article
Topalian N, Picard S, Riveline JP, Canha D, et al.
Diabetes, obesity & metabolism · 2024 · Letter
Reznik Y, Bonnemaison E, Fagherazzi G, Renard E, et al.
Diabetes & metabolism · 2026 · Journal Article
Rollet M, Aguayo GA, Canha D, Riveline JP, et al.
JMIR research protocols · 2025 · Journal Article
Rollet M, Aguayo GA, Riveline JP, Cosson E, et al.
Diabetic medicine : a journal of the British Diabetic Association · 2025 · Journal Article
Canha D, McMahon V, Schmitz S, De Beaufort C, et al.
Cardiovascular diabetology · 2025 · Journal Article
Salle L, Julla JB, Fagherazzi G, Gourdy P, et al.
Cardiovascular diabetology · 2024 · Journal Article
Cosson E, Auzanneau M, Aguayo GA, Karges W, et al.
Circulation research · 2024 · Journal Article
Julla JB, Girard D, Diedisheim M, Saulnier PJ, et al.
Diabetes & metabolism · 2025 · Journal Article
Topalian N, Picard S, Riveline JP, Canha D, et al.
Diabetes technology & therapeutics · 2023 · Multicenter Study
Diedisheim M, Pecquet C, Julla JB, Carlier A, et al.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025 · Journal Article
Vidal-Trécan T, Julla JB, El Khoury T, Venteclef N, et al.
Diabetes, obesity & metabolism · 2022 · Journal Article
Riveline JP, Wojtusciszyn A, Guerci B, Alves C, et al.
Diabetes technology & therapeutics · 2022 · Journal Article
El Fatouhi D, Héritier H, Allémann C, Malisoux L, et al.
Diabetes care · 2024 · Journal Article
Renard E, Weinstock RS, Aleppo G, Bode BW, et al.
Diabetic medicine : a journal of the British Diabetic Association · 2025 · Journal Article
Canha D, McMahon V, Schmitz S, De Beaufort C, et al.
Use of Flash Glucose-Sensing Technology for 12 months as a Replacement for Blood Glucose Monitoring in Insulin-treated Type 2 Diabetes
<strong>Article full text</strong> <br> The full text of this article can be found <b>here</b>.<br> <br> <strong>Provide enhanced digital features for this article</strong><br> If you are an author of this publication an
Use of Flash Glucose-Sensing Technology for 12 months as a Replacement for Blood Glucose Monitoring in Insulin-treated Type 2 Diabetes
<strong>Article full text</strong> <br> The full text of this article can be found <b>here</b>.<br> <br> <strong>Provide enhanced digital features for this article</strong><br> If you are an author of this publication an
Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial
<strong>Article full text</strong> <br> The full text of this article can be found <b>here</b>.<br> <br> <strong>Provide enhanced digital features for this article</strong><br> If you are an author of this publication an
Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial
<strong>Article full text</strong> <br> The full text of this article can be found <b>here</b>.<br> <br> <strong>Provide enhanced digital features for this article</strong><br> If you are an author of this publication an
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025 · Journal Article
Beltrand J, Benhamou PY, Choleau C, Braithwaite B, et al.
Diabetes technology & therapeutics · 2024 · Journal Article
Riveline JP, Levrat-Guillen F, Detournay B, Vicaut E, et al.
Patient preference and adherence · 2022 · Journal Article
Reach G, Benarbia L, Benhamou PY, Delemer B, et al.